- Home
- SDA vs AUPH Comparison
SDA vs AUPH Comparison
Compare SDA & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SDA | AUPH |
|---|---|---|
| Founded | 2007 | 1993 |
| Country | China | Canada |
| Employees | 560 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.5M | 1.9B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | SDA | AUPH |
|---|---|---|
| Price | $1.74 | $14.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $4.75 | ★ $17.25 |
| AVG Volume (30 Days) | 420.3K | ★ 1.1M |
| Earning Date | 04-27-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | N/A | ★ 2.07 |
| Revenue | N/A | ★ $283,055,000.00 |
| Revenue This Year | $12.01 | $16.53 |
| Revenue Next Year | $15.55 | $16.24 |
| P/E Ratio | ★ N/A | $7.06 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $1.54 | $6.83 |
| 52 Week High | $4.42 | $16.54 |
Technical Indicators
Market Signals| Indicator | SDA | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 37.35 | 48.71 |
| Support Level | $1.54 | $13.52 |
| Resistance Level | $2.18 | $15.23 |
| Average True Range (ATR) | 0.13 | 0.46 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 0.00 | 33.82 |
Price Performance
Historical ComparisonAbout SDA SunCar Technology Group Inc.
SunCar Technology Group Inc operates digital automotive aftersales market service platform and vehicle insurance technology platform. It develops and operates online platforms that connect drivers in China with a range of aftermarket automotive services and insurance coverage options from a nationwide network of service providers. These comprehensive digital systems are built on SunCar's multi-tenant, cloud-based platform.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.